Merck Launches Late-stage Trial for MK-1084 and KEYTRUDA in Lung Cancer Treatment
Thursday, 4 April 2024, 12:29
Merck Launches Late-stage Trial for Lung Cancer Combo Therapy
Merck has initiated a Phase 3 clinical trial for its experimental drug, MK-1084, in combination with KEYTRUDA for the treatment of metastatic non-small cell lung cancer. The trial aims to evaluate the efficacy and safety of this novel therapy in a late-stage setting.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.